High-dose chemotherapy and autologous stem cell transplantation in elderly primary CNS lymphoma patients - retrospective chart review

High-dose chemotherapy and autologous stem cell transplantation in elderly primary CNS lymphoma patients - retrospective chart review - HDT-ASCT in elderly PCNSL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009037

Enrollment

Registered

2015-08-17

Start date

2015-03-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C85.9

Interventions

Group 1: Investigation of outcome and feasibility of high-dose chemotherapy followed by autologous stem cell transplantation in elderly PCNSL patients.

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: Immunocompetent patients with biopsy proven PCNSL who underwent HDT-ASCT, age at diagnosis >/=65 years

Exclusion criteria

Exclusion criteria: Congenital or acquired immunodeficiency, age < 65 years

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS)	—

Secondary

Measure	Time frame
Remission status before HCT-ASCT Adverse events during HCT-ASCT Remission status after HCT-ASCT Overall Survival (OS)	—

Countries

Germany, United Kingdom

Contacts

Public ContactElisabeth Schorb

Innere Medizin I, Universitätsklinikum Freiburg

elisabeth.schorb@uniklinik-freiburg.de004976127033110

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026